רבלימיד 15 מ"ג

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

LENALIDOMIDE 15 MG

Disponibbli minn:

NEOPHARM SCIENTIFIC LTD

Kodiċi ATC:

L04AX04

Għamla farmaċewtika:

CAPSULES

Rotta amministrattiva:

PER OS

Manifatturat minn:

CELGENE EUROPE LTD, UK

Grupp terapewtiku:

LENALIDOMIDE

Indikazzjonijiet terapewtiċi:

1. Treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Data ta 'l-awtorizzazzjoni:

2009-04-01